newsfilter
← Latest News
GlobeNewswire·

LianBio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Phase 3 registrational trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) ongoing Mavacamten granted breakthrough therapy designation in China for the treatment of patients with oHCM Infigratinib